Tevogen Bio (TVGN) said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development.
The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines that mainly induce a B cell response.
Tevogen Bio said that similar to its lead product candidate TVGN 489, the vaccine can target the entire viral genome, helping to mitigate a risk posed by mutations.
The company's shares were down over 5% in recent trading.
Price: 1.08, Change: -0.06, Percent Change: -5.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.